Top Banner
PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga
12

PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

Dec 17, 2015

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

PHARMAC’s Māori Responsiveness Strategy Action PlanMarama Parore

Ngati Whatua, Ngapuhi, Ngati Kahu

GM Access & Optimal Use – Pou Arahi Te Whaioranga

Page 2: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

Gaps in Māori use of medicine- after adjusting for age, burden of disease (need) and relevant to the Pharmaceutical Schedule

Page 3: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

Te Tiriti o WaitangiPHARMAC acknowledges the special relationship that exists

between the Crown and Maori, and recognises the articles of the Treaty of Waitangi; and the principles

Partnership;

Protection;

Participation.

Page 4: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

Goal

To ensure that Māori have:

Access to subsidised medicines

The knowledge to use these medicines safely and appropriately

Page 5: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

History of the Māori Responsiveness Strategy

2001: 15 consultation hui

2002: Māori Responsiveness Strategy I

2007-2012: Māori Responsiveness Strategy II

2012-2017: Māori Responsiveness Strategy III

Page 6: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

“there are barriers to accessing health professionals – cost, attitude to Māori, being treated as a number”

“patients are not provided with sufficient information from chemists”

“you aren’t told everything and you can’t ask what you don’t know”

“chemist labels are confusing and hide the contents of the medicine”

“Confusion around trade names versus generic medicines”

“Medications need to be explained”

“Print on small bottles are too little to read”

“Kaumatua do not like to ask questions and are sometimes treated like they are thick”

“Māori are unsure of medicines – there is an air of mistrust and often they just need understanding”

PHARMAC survey - Key points from hui

Page 7: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

Māori Responsiveness Strategy

– Māori strategic priorities

– Internal capability

– Data collection and analysis

– Funding and procurement

– Information on subsidised medicines and optimal use

– Māori representation and participation

Page 8: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

PHARMAC commitment to Māori Health

Page 9: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

www.hrphow.co.nz

Page 10: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

• He Manawa Tahi Koiora Tini

• Cardiovascular Disease – key priority

• Tane Ora – Māori and Pacific Island men 35+ years

• Māori and Pacific Island men die of heart disease, 10-14 years earlier than non-Māori and non-Pacific Island men

• www.oneheartmanylives.co.nz

Page 11: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

• Asthma is the leading cause of childhood admissions to hospital

• Māori and Pacific people are more likely to be hospitalised for asthma and have more severe chronic symptons

• The ratio of SABA to ICS dispensings is higher in Māori and Pacific children

• www.spacetobreathe.co.nz

Page 12: PHARMAC’s Māori Responsiveness Strategy Action Plan Marama Parore Ngati Whatua, Ngapuhi, Ngati Kahu GM Access & Optimal Use – Pou Arahi Te Whaioranga.

Discussion